Radius Health Inc (RDUS) Receives Consensus Recommendation of “Hold” from Brokerages
Radius Health Inc (NASDAQ:RDUS) has received an average recommendation of “Hold” from the twelve research firms that are currently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $52.00.
Several brokerages recently weighed in on RDUS. ValuEngine raised shares of Radius Health from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st. Citigroup began coverage on shares of Radius Health in a report on Wednesday, December 6th. They issued a “neutral” rating and a $30.00 target price for the company. Cantor Fitzgerald set a $58.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Friday, December 15th. BidaskClub downgraded shares of Radius Health from a “sell” rating to a “strong sell” rating in a report on Thursday, December 7th. Finally, Jefferies Group dropped their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating for the company in a report on Friday, November 3rd.
In other Radius Health news, major shareholder Growth N. V. Biotech purchased 50,000 shares of the stock in a transaction that occurred on Wednesday, October 25th. The stock was purchased at an average price of $32.85 per share, with a total value of $1,642,500.00. Following the acquisition, the insider now owns 5,548,799 shares in the company, valued at $182,278,047.15. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Brent Hatzis-Schoch purchased 1,778 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was acquired at an average cost of $28.09 per share, with a total value of $49,944.02. Following the acquisition, the vice president now owns 2,278 shares in the company, valued at approximately $63,989.02. The disclosure for this purchase can be found here. Insiders have acquired a total of 158,578 shares of company stock valued at $4,659,916 in the last three months. Insiders own 15.00% of the company’s stock.
Several large investors have recently made changes to their positions in the stock. Belpointe Asset Management LLC bought a new position in shares of Radius Health in the 3rd quarter valued at about $474,000. Cubist Systematic Strategies LLC bought a new position in shares of Radius Health in the 3rd quarter valued at about $110,000. Point72 Asset Management L.P. bought a new position in shares of Radius Health in the 3rd quarter valued at about $17,236,000. Orbimed Advisors LLC lifted its holdings in shares of Radius Health by 59.5% in the 3rd quarter. Orbimed Advisors LLC now owns 1,122,800 shares of the biopharmaceutical company’s stock valued at $43,284,000 after acquiring an additional 418,700 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. lifted its holdings in shares of Radius Health by 28.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 180,901 shares of the biopharmaceutical company’s stock valued at $6,974,000 after acquiring an additional 40,006 shares during the last quarter.
Radius Health (NASDAQ:RDUS) opened at $30.98 on Monday. The firm has a market cap of $1,344.00, a price-to-earnings ratio of -5.71 and a beta of 1.09. The company has a quick ratio of 12.79, a current ratio of 12.87 and a debt-to-equity ratio of 0.53. Radius Health has a 1-year low of $24.66 and a 1-year high of $49.16.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The company had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same period in the prior year, the company earned ($1.07) earnings per share. analysts expect that Radius Health will post -5.57 earnings per share for the current fiscal year.
WARNING: This news story was first reported by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://theolympiareport.com/2017/12/25/radius-health-inc-rdus-receives-consensus-recommendation-of-hold-from-brokerages.html.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with Analyst Ratings Network's FREE daily email newsletter.